Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

Summary

Novartis agreed to acquire Myricx Bio, a Brandon Capital portfolio company, to advance a new class of cancer therapeutics. The acquisition aims to expand Novartis's oncology pipeline with novel therapeutic approaches.